Description of long-term polypharmacy among schizophrenia outpatients

Social Psychiatry and Psychiatric Epidemiology

Volumn 48, Issue 4, 2013, Pages 631-638

  Suokas, Jaana T ^a,b   Suvisaari, Jaana M ^a   Haukka, Jari ^c,d   Korhonen, Pasi ^c,e   Tiihonen, Jari ^a,f,g,h  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c EPID Research Oy   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e StatFinn Oy   (Finland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antipsychotics; Long term; Outpatient treatment; Polypharmacy; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG COMBINATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; POLYPHARMACY; PREVALENCE; REGISTER; SCHIZOPHRENIA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; POLYPHARMACY; PREVALENCE; REGISTRIES; SCHIZOPHRENIA;

EID: 84876407787     PISSN: 09337954     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00127-012-0586-6     Document Type: Article

References (39)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, William Keller W (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71-93
2. Finnish guidelines for treatment of schizophrenia. The Finnish Medical Society Duodecim and the Finnish Psychiatric Association. http://www. terveysportti.fi/xmedia/hoi/hoi35050.pdf. Accessed 16 Nov 2010
3. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1-56
4. National institute for clinical excellence (NICE) (2009) Clinical Guideline CG82 Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. http://www.nice.org. uk/nicemedia/pdf/CG82NICEGuideline.pdf. Accessed 16 Nov 2010
5. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covel NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702-708
6. Tamminga CA (2011) When is polypharmacy an advantage? Am J Psychiatry 168(7):663
7. Stahl SM (2002) Antipsychotic polylpharmacy: squandering precious resources? J Clin Psychiatry 63:93-94
8. Correll CU, Rummel-Klulge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combination vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443-457
9. Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):720-721
10. Fleschhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, Loze J-Y, Hennicken D, Kerselaers WS (2010) Effects on adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115-1125
11. McCue RE, Waheed R, Urcuyo L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64:984-989
12. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65:1377-1388
13. Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023-1033
14. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, Walpoth M, Fleischhacker W (2005) Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77:25-34
15. Faries D, Ascher-Svanum H, Zhu B, Correl C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotic. BMC Psychiatry 5:26
16. Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355-362
17. Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57:1084-1101
18. Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV (2007) Antipsychotic polypharmacy trends among Medical beneficiaries with schizophrenia in San Diego county, 1999-2004. Psychiatr Serv 58(7):1007-1010
19. Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A (2007) A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13(2):129-137
20. Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann R (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571-582
21. Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345-367
22. Jaffe AB, Levine J (2003) Antipsychotic medication coprescribing in the large state hospital system. Pharmacoepidemiol Drug Saf 12:41-48
23. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55-59
24. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC (2006) Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84:90-99
25. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini R (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patient: case-control study of risks versus benefits. Am J Psychiatry 161:700-706
26. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for State Mental Health Policy. Schizophr Bull 28(1):75-84
27. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122-127
28. Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A, Mortensen P (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71(2):103-108
29. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. Lancet 374:620-627
30. Tiihonen J, Suokas J, Suvisaari J, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476-483
31. Tiihonen J, Haukka J, Haddad P, Patel M, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603-609
32. ATC/DDD Index 2006. http://www.whocc.no/atc-ddd-index/. Accessed 24 Aug 2011
33. Nielsen LH, Løkkegaard E, Andreasen AH, Keiding N (2008) Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 17:384-388
34. Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenia patients: preponderance of off-label drug use. PLoS ONE 3(9):e3150
35. Sernyak M, Rosenheck R (2004) Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 65:107-117
36. Längle G, Steiner T, Weiser P, Schep W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R (2012) Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 125:372-381
37. Perälä J, Saarni SI, Ostamo A, Pirkola S, Haukka J, Härkänen T, Koskinen S, Lönnqvist J, Suvisaari J (2008) Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res 106:337-347
38. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18-28
39. Terevnikov F, Stenberg J, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G (2011) Add-on mirtazapine improves depressive symptoms in schizophrenia: a douple-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol 26:188-193